autologous dendritic cell vaccine (Dartmouth-Hitchcock Medical Center)

This autologous dendritic cell vaccine is a personalized cancer immunotherapy developed by Dartmouth-Hitchcock Medical Center for the treatment of advanced melanoma (Stage III or IV). The therapy involves harvesting a patient's own dendritic cells and maturing them in the presence of autologous tumor cell lysate, which contains a broad spectrum of the patient's specific tumor-associated antigens. Once these matured and pulsed dendritic cells are re-administered to the patient, they function as professional antigen-presenting cells, priming and activating the patient's T cells to recognize and eliminate melanoma cells. This approach aims to generate a robust, specific, and durable anti-tumor immune response tailored to the individual's unique tumor profile.

Other names

autologous dendritic cells pulsed with autologous tumor cell lysatetherapeutic autologous dendritic cellsautologous tumor cell vaccineEn Vivo Matured Dendritic Cell Therapy